A Phase 3 interventional study of Azithromycin and Doxycycline in Urethritis, sponsored by University of Washington. Completed at 1 site in United States. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.
Sponsored by University of Washington · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis.
Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination).
Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms.
Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
OBJECTIVES
The primary objective of this study is to determine the relative effectiveness of azithromycin and doxycycline in eradicating Mycoplasma genitalium and Ureaplasmas among men with nongonococcal urethritis (NGU).
Secondary objectives of this study are to:
STUDY DESCRIPTION
1200 men with NGU, ages 16 and older, will be enrolled in a randomized double-blinded treatment trial. Urine samples, oral swabs, and urethral swabs will be obtained from each subject at the initial clinic visit. Urine specimens will be tested for M. genitalium and Ureaplasma. Study participants will be randomly assigned to receive one of two pre-packaged treatments: active doxycycline plus placebo azithromycin or active azithromycin plus placebo doxycycline. Subjects will complete a questionnaire, and will be given a simple standardized log in which they will be asked to keep track of adherence to the study drug, record solicited adverse events, note when symptoms disappear and/or reappear, and document sexual activity between study visits.
Subjects who test positive for M. genitalium or Ureaplasmas at the initial clinic visit will be asked to return for at least two follow-up study visits: at approximately 3 and 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis and re-tested for M. genitalium and Ureaplasmas. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visits will receive a blinded treatment packet containing the alternate medication, or will be offered open-label moxifloxacin if the alternate treatment regimen was administered at the prior follow-up study visit. If additional treatment is administered at the 6-week follow-up study visit, a fourth study visit will be scheduled to occur approximately 9 or 10 weeks following the initial clinic visit.
Study participants who were negative for M. genitalium and Ureaplasma at enrollment will be asked to return for evaluation for a single follow-up study visit, approximately 3 weeks after the initial clinic visit. At this visit they will complete the follow-up questionnaire and provide specimens for future testing.
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active azithromycin (1g) and placebo doxycycline
Drug: Azithromycin
Active doxycycline and placebo azithromycin
Drug: Doxycycline
two 500mg tablets or four 250mg tablets administered as a single dose
Also known as: Zithromax, Zmax
one 100mg capsule administered twice daily for seven days
Also known as: Doryx, Doxychel, Monodox, Oracea, Periostat, Vibra-Tabs, Vibramycin
mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit
Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)
Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit
Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit
Time frame: 3 weeks (allowable window 2-5)
Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit
Proportion of men with M. genitalium at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.
Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit
Proportion of men with Ureaplasma urealyticum at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.
Time frame: approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)
Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Azithromycin
In vitro susceptibiities of M. genitalium to azithromycin
Time frame: baseline
Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline
In vitro susceptibilities of M. genitalium to doxycycline
Time frame: baseline
Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2
In vitro susceptibilities of U. urealyticum biovar 2
Time frame: baseline
Minimum Inhibitory Concentrations (MIC) of U. Parvum
In vitro susceptibilities of U. parvum
Time frame: baseline
Men were recruited from a sexually transmitted diseases clinic in Seattle, Washington from January 2007 to July 2011
| Milestone | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin |
|---|---|---|
| Started | 304 | 302 |
| Completed | 245 | 238 |
| Not completed | 59 | 64 |
Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)
| participants | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin |
|---|---|---|
| mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit | 15 | 8 |
Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit
| participants | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin |
|---|---|---|
| mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit | 39 | 38 |
Proportion of men with M. genitalium at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.
| participants | Active Azithromycin+Placebo Doxycycline | Active Doxycycline+Placebo Azithromycin |
|---|---|---|
| Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit | 24 | 13 |
Proportion of men with Ureaplasma urealyticum at the initial study visit who had clinical cure, defined as \<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.
| participants | Active Azithromycin+Placebo Doxycycline | Active Doxycycline+Placebo Azithromycin |
|---|---|---|
| Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit | 43 | 40 |
In vitro susceptibiities of M. genitalium to azithromycin
| Participants | Cultivated Isolates |
|---|---|
| MIC range <=0.001 - 0.004 ug/ml | 31 |
| MIC range >8 ug/ml | 25 |
In vitro susceptibilities of M. genitalium to doxycycline
| MIC (ug/mL) | Cultivated Isolates |
|---|---|
| Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline | 0.5 (0.125 to 2.0) |
In vitro susceptibilities of U. urealyticum biovar 2
| MIC (ug/mL) | Azithromycin | Doxycycline | Moxifloxacin |
|---|---|---|---|
| Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2 | 1.00 (0.25 to 2.00) | 0.5 (0.125 to 1.00) | 0.5 (0.25 to 1.00) |
In vitro susceptibilities of U. parvum
| MIC (ug/mL) | Azithromycin | Doxycycline | Moxifloxacin |
|---|---|---|---|
| Minimum Inhibitory Concentrations (MIC) of U. Parvum | 0.5 (0.125 to 2.00) | 0.25 (0.125 to 0.50) | 0.25 (0.125 to 0.50) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Azithromycin + Placebo Doxycycline | — | 1/304 (0.3%) | 53/304 (17.4%) |
| Active Doxycycline + Placebo Azithromycin | — | 3/302 (1%) | 56/302 (18.5%) |
| Event | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin |
|---|---|---|
| Gun shot woundInjury, poisoning and procedural complications | 0/304 | 1/302 |
| Broken legInjury, poisoning and procedural complications | 0/304 | 1/302 |
| Optic neuritisEye disorders | 0/304 | 1/302 |
| Unstable mental statusPsychiatric disorders | 1/304 | 0/302 |
| Event | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin |
|---|---|---|
| NauseaGastrointestinal disorders | 28/304 | 36/302 |
| DiarrheaGastrointestinal disorders | 31/304 | 35/302 |
| OtherGastrointestinal disorders | 12/304 | 17/302 |
| VomitingGeneral disorders | 6/304 | 7/302 |
| RashGeneral disorders | 6/304 | 7/302 |
| Age, Continuous(years) | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin | Total |
|---|---|---|---|
| Mean | 34.1 ± 9.8 | 33.3 ± 10.1 | 33.7 ± 10.0 |
| Sex: Female, Male(Participants) | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 304 | 302 | 606 |
| Region of Enrollment(participants) | Active Azithromycin + Placebo Doxycycline | Active Doxycycline + Placebo Azithromycin | Total |
|---|---|---|---|
| United States | 304 | 302 | 606 |
The record gives a start of Jan 2007, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azithromycin · Doxycycline
Urethritis